Buscar resultados de ensayos clínicos
Pancreatic Neuroendocrine Tumor - 45 Studies Found
Estado | Estudiar |
Completed |
Nombre del estudio: BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. Condición: Pancreatic Neuroendocrine Tumors (pNET) Fecha: 2012-07-06 Intervenciones: Drug: BEZ235 (Stage 1) The investigational study drug used in this trial was BEZ235, which was supplied |
Active, not recruiting |
Nombre del estudio: RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors Condición: Pancreatic Neuroendocrine Tumor Fecha: 2007-12-17 Intervenciones:
|
Recruiting |
Nombre del estudio: Evaluation of Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria Condición: Pancreatic Neuroendocrine Tumors Fecha: 2016-07-20 |
Completed |
Nombre del estudio: Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Condición: Pancreatic Neuroendocrine Tumors Fecha: 2010-05-10 Intervenciones: Drug: Sunitinib Sunitinib capsule will be given orally at continuous daily dosing with a dose of 37.5 mg |
Recruiting |
Nombre del estudio: The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors Condición: Pancreatic Neuroendocrine Tumors Fecha: 2014-10-15 Intervenciones: Drug: sunitinib subjects will be enrolled to receive at least one dose of sunitinib orally at 37.5 mg on |
Not yet recruiting |
Nombre del estudio: Phase II Study to Evaluate Efficacy of Rechallenge With Sunitinib in Patients With Metastatic Pancreatic Neuroendocrine Tumor (pNETs) Who Previously Failed to Sunitinib Condición: Pancreatic Neuroendocrine Tumour Metastatic Fecha: 2016-03-16 Intervenciones: Drug: Sunitinib Sunitinib 37.5 mg/day |
Completed |
Nombre del estudio: Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor Condición: Advanced Well-differentiated Pancreatic Neuroendocrine Tumor Fecha: 2013-04-29 Intervenciones: Drug: temozolomide or dacarbazine-based chemotherapy, endostatin |
Recruiting |
Nombre del estudio: 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors Condición: Gastro-entero-pancreatic Neuroendocrine Tumors Fecha: 2016-04-07 Intervenciones:
|
Not yet recruiting |
Nombre del estudio: Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment Condición: Pancreatic Neuroendocrine Tumors in MEN1 Fecha: 2016-03-02 Intervenciones: Drug: Somatostatin-Analog A long-acting somatostatin-analog will be applied. |
Terminated |
Nombre del estudio: Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors Condición: Pancreatic Neuroendocrine Tumors (pNET) Fecha: 2012-06-25 Intervenciones:
|